

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

3DMed

思路迪

3D Medicines Inc.

思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE STRATEGIC COOPERATION AGREEMENT AND UPDATES ON CIVIL PROCEEDINGS

Reference is made to the announcement of the Company dated July 2, 2025 in respect of the Strategic Cooperation Agreement, and the announcements of the Company dated January 24, 2025 and February 17, 2025 in respect of the Civil Ruling. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the aforementioned announcements.

The Strategic Cooperation Agreement

The Consideration of RMB98.0 million was determined after arm's length negotiation between the Company and Qingdao Hainuo, with reference to, among others, (i) the total value of RMB458.5 million in bank deposits and assets subject to the Preservation Order; (ii) the potential financial and operational challenges that could arise from the prolonged enforcement of the Preservation Order; (iii) the cost and time that would be required to discharge the Preservation Order upon the conclusion of the civil proceedings between the Company and Qingdao Hainuo; and (iv) the fact that the Consideration would be refunded or will offset from final settlement.

Following the signing of the Strategic Cooperation Agreement, Qingdao Hainuo and the Group had jointly submitted an application to the Qingdao Intermediate People's Court (the "**Court**") for the withdrawal of the civil proceedings, and the discharge of the Preservation Order. Thus, the Strategic Cooperation Agreement not only laid the groundwork for resolving the disputes but also served as a stepping stone for fostering future collaboration between the parties.

In the Strategic Cooperation Agreement, Qingdao Hainuo also expressed confidence in the Company's future growth and recognized that the Company had been significantly undervalued. The Strategic Cooperation Agreement memorialized the mutual commitment of the Company and Qingdao Hainuo to work towards a mutually agreeable resolution of the legal disputes between them, including (i) a preliminary indication of interest by the Company to purchase the equity interests held by Qingdao Hainuo in 3D-Med Shanghai in five years, and (ii) a preliminary indication of interest by Qingdao Hainuo to subscribe for the Company's Shares in the future. At present, no definitive agreement has been entered into by the Company and Qingdao Hainuo as to the aforementioned transactions. The Company will make further announcement(s) in accordance with the Listing Rules and the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) as and when appropriate.

The Consideration is funded by internal resources of the Group. The Strategic Cooperation Agreement would not have a material adverse impact on the Group, as it led to the discharge of the Preservation Order, which in turn strengthened our operational and financial stability. Please refer to the “Reasons for and Benefits of Entering into the Strategic Cooperation Agreement” section in the Company’s announcement dated July 2, 2025 for the reasons considered by the Board when entering into the Strategic Cooperation Agreement.

Updates on the Civil Proceedings

The Company and Qingdao Hainuo have been negotiating to seek a mutually beneficial solution. Both parties have mutually agreed in principle to end the litigation process. As stated above, following the signing of the Strategic Cooperation Agreement, the Group and Qingdao Hainuo had jointly submitted an application to the Court for the withdrawal of the civil proceedings, and the discharge of the Preservation Order. As of the date of this announcement, all of the Company’s accounts were released from the Preservation Order, and the Preservation Order has been discharged.

For the avoidance of doubt, in the unlikely event if the withdrawal application is disallowed by the Court, and the dispute is ultimately resolved in the Company’s favor, the Consideration of RMB98.0 million will be refunded. On the other hand, if a settlement is reached before the civil proceedings conclude, the Consideration will offset the settlement amount.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong
July 14, 2025

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.